Having trouble accessing articles? Reset your cache.

NTx-265: Additional Phase IIb data

A subset analysis of patients who received occupational therapy (OT) (about 25%) in the double-blind, international Phase IIb REGENESIS trial in 96 patients showed that NTx-265 significantly reduced NIHSS

Read the full 295 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE